

ASX Announcement

12 August 2021

Application of Listing Rule 11 MedTech Growth Services Agreement

Rewardle Holdings Limited (ASX:RXH) ("**Rewardle**" or the "**Company**") is pleased to provide the following announcement with respect to the application of Listing Rule 11.1 to the ("**Transaction**"), the subject of the announcement released on 2 August 2021, titled "MedTech Growth Services Agreement".

The ASX has confirmed that Listing Rule 11.1 does not apply to the Transaction which included the execution of a binding Terms Sheet to provide services to Cardiac Rhythm Diagnostics ("**CRD**"), a fast-growing MedTech business that is developing a disruptive, technology enabled cardiac diagnostics service for local GPs.

The Company is looking forward to progressing its engagement with CRD and continuing to execute its strategy.

Yours sincerely



Ruwan Weerasooriya
Executive Chairman

This ASX release has been authorised for release by the Board of Directors.

For more information please contact:
Ruwan Weerasooriya (Founder and Managing Director)
Email: ruwan@rewardle.com
Mobile: 0412448769